Moderna Stock News

Although it is off its high from earlier this morning, Moderna (MRNA) is still having one of its best days in weeks.

Young, healthy people may choose not to get boosted if they''re not concerned about infection or mild disease, Moderna President Stephen Hoge said.

Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.

The Nasdaq Composite continued to lose ground, but these stocks held up.

Moderna Inc (NASDAQ: MRNA ) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be … Full story available on Benzinga.com

Gainers Volt Information Sciences, Inc. (NYSE: VOLT ) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI ) shares climbed 36.5% to $4.3001. Turquoise Hill Resources Ltd. (NYSE: TRQ ) gained 32.4% to $26.68 after Rio Tinto proposed to acquire the company at C$34 per share. Mullen Automotive, Inc. (NASDAQ: MULN ) rose 27% to $1.7153 after jumping 26% on Friday. Molecular Data Inc. (NASDAQ: MKD ) rose 25.2% to $0.1930 after dropping around 12% on Friday. Alset EHome International Inc. (NASDAQ: AEI ) shares rose 20.2% to $0.5168 after jumping 24% on Friday. Moderna, Inc. (NASDAQ: MRNA ) gained 18.9% to $164.29 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine. BioNTech SE (NASDAQ: BNTX ) jumped 16.7% to $158.32. The Pfizer- BioNTech vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15.

Midday Movers: Banking Stocks, Moderna, and Mullen Automotive Rise

Moderna stock rocketed Monday after the company dosed the first participant in a study of its potential HIV vaccine.

Many vaccine makers are surging in Monday trading amid concerns over a new COVID-19 variant, deltacron, and as China experiences its worst outbreak since early 2020.

The stock is trying to settle above the $165 level.

Moderna Inc (NASDAQ: MRNA ) shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer … Full story available on Benzinga.com

Many vaccine makers are surging in Monday trading amid concerns over a new COVID-19 variant, deltacron, and as China experiences its worst outbreak since early 2020.

NEW YORK , March 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AZN, BUD, MRNA, LMT, and WFC. … Full story available on Benzinga.com

Meme stocks, telehealth and remote work went mainstream while people renovated their homes and demanded more from employers. Which changes will stick?

Although US crude oil futures traded lower by more than 4% on Monday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or tha